Cipla reported a 39% drop in first-quarter net profit, a stark reflection of the headwinds facing Indian pharmaceutical exporters amid escalating US trade tensions.
The Mumbai-based generic drugmaker attributed the decline to the broader macroeconomic environment, specifically highlighting the impact of proposed tariffs on generic drugs entering the United States.
Despite the bottom-line pressure, the company pointed to resilience in its domestic operations.
Cipla’s 'One India' business segment recorded quarterly sales of ₹3,452 crore, marking its highest-ever quarterly performance.
Management emphasized that this diversified model, which balances domestic growth against international volatility, is central to the company’s strategy to weather the current tariff-related uncertainties.
The earnings miss arrives as US trade policy continues to reshape global supply chains.